FDA warned Ambaya Gold Health Products that website and social media claims made its supplements and silver products unapproved new drugs.
What happened
FDA reviewed www.ambayagold.com in April and November 2023 and the company's Facebook page, which directs consumers to the website. FDA found claims that products such as Brain Balance, Immune System Boost, Silver Solution, and others are intended to cure, mitigate, treat, or prevent disease or affect body structure or function. The letter says several of these products are unapproved new drugs; Silver Spray and Magnesium Oil Spray also do not meet applicable over-the-counter drug rules.
What FDA found
Website and social media claims show the products are intended to cure, mitigate, treat, or prevent disease or affect the body's structure or function, making them drugs.
FD&C Act section 201(g)(1)(B)/(C) [21 U.S.C. 321(g)(1)(B)/(C)]The listed products are not generally recognized as safe and effective for the claimed uses, so they are new drugs that need FDA approval before sale.
FD&C Act sections 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]Silver Spray is a first aid antiseptic containing silver, and no silver-containing over-the-counter drugs are generally recognized as safe and effective under FDA's final determination.
FD&C Act section 505G(a)(5); 21 CFR part 330Silver Spray is marketed without an approved application, making it an unapproved new drug.
FD&C Act sections 505(a), 301(d) [21 U.S.C. 355(a), 331(d)]Magnesium Oil Spray is labeled as an external analgesic but its ingredients do not conform to FDA's over-the-counter monograph M017 and are not permitted active ingredients.
FD&C Act section 505G; OTC Monograph M017; 21 CFR 201.66(b)(2)FDA says it is not aware of adequate and well-controlled trials showing Magnesium Oil Spray is generally recognized as safe and effective for its labeled uses.
FD&C Act section 505G
What FDA wants
FDA asks the company to correct the violations described in the letter. The provided letter text does not state a response deadline.
Who should pay attention
- supplement and herbal product brands that make disease claims online
- retailers and distributors selling silver or colloidal silver products
- companies selling over-the-counter antiseptic or analgesic sprays
This is a summary. Read the original letter on fda.gov.